Bellevue Group’s iShares Biotechnology ETF IBB Stock Holding History

Bellevue Group’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-28,000	Closed	-$3.41M	–	140
2018 Q3	$3.41M	Buy	+28,000	New	+$3.3M	0.22%	90
2018 Q1	–	Sell	-13,500	Closed	-$1.44M	–	127
2017 Q4	$1.44M	Sell	13,500 -13,500	-50%	-$1.44M	0.15%	96
2017 Q3	$3M	Buy	27,000 +6,000	+29%	+$641K	0.31%	68
2017 Q2	$2.17M	Sell	21,000 -15,000	-42%	-$1.48M	0.26%	78
2017 Q1	$3.52M	Buy	36,000 +24,000	+200%	+$2.3M	0.47%	60
2016 Q4	$1.06M	Sell	12,000 -28,500	-70%	-$2.59M	0.22%	82
2016 Q3	$3.91M	Buy	40,500 +15,000	+59%	+$1.43M	0.71%	46
2016 Q2	$2.19M	Buy	25,500 +18,000	+240%	+$1.62M	0.41%	69
2016 Q1	$652K	Buy	+7,500	New	+$671K	0.12%	104

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Bellevue Group's IBB Position: Q4 2018 in Review

Bellevue Group sold out of iShares Biotechnology ETF (IBB) in Q4 2018, closing a stake of 28,000 shares — an estimated $3.41M sold.

Bellevue Group first reported a position in IBB in Q1 2016 and held it in 9 quarters. The position peaked at $3.91M in Q3 2016. 649 funds tracked by Wall St. Rank hold IBB as of Q4 2018.

Bellevue Group reported no remaining iShares Biotechnology ETF position as of Q4 2018 after selling out during the quarter.
Bellevue Group sold 28,000 iShares Biotechnology ETF shares in Q4 2018, an estimated $3.41M.
Bellevue Group first reported a position in iShares Biotechnology ETF in Q1 2016 and held it in 9 quarters.
Bellevue Group's iShares Biotechnology ETF position peaked at $3.91M in Q3 2016.
649 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2018.

Based on Bellevue Group's 13F filing for Q4 2018, filed 12 Feb 2019.